When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches
暂无分享,去创建一个
J. McMurray | S. Pocock | N. Geller | B. Pitt | F. Zannad | W. Remme | J. Borer | Wendy Gattis Stough
[1] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[2] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[3] Data and Safety Monitoring , 2014 .
[4] K. Dickstein,et al. The data monitoring experience in the MOXCON trial. , 2004, European Heart Journal.
[5] Ralph D'Agostino,et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.
[6] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[7] K. Schulz,et al. Multiplicity in randomised trials II: subgroup and interim analyses , 2005, The Lancet.
[8] Sydes,et al. A proposed charter for clinical trial data monitoring committees: helping them to do their job well , 2005, The Lancet.
[9] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[10] S. Kaul,et al. By Jove! What is a clinician to make of JUPITER? , 2010, Archives of internal medicine.
[11] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[12] D. DeMets,et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. , 1999, The New England journal of medicine.
[13] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[14] A. Moss,et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.
[15] R. Collins,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.
[16] Bertram Pitt,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.
[17] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[18] B. Freidlin,et al. Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Ridker. The JUPITER Trial: Results, Controversies, and Implications for Prevention , 2009, Circulation. Cardiovascular quality and outcomes.
[20] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[21] P. Ridker,et al. The JUPITER Trial: responding to the critics. , 2010, The American journal of cardiology.
[22] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[23] N. Geller,et al. When should data and safety monitoring committees share interim results in cardiovascular trials? , 2008, JAMA.
[24] J. Whitehead,et al. Stopping a trial early in oncology: for patients or for industry? , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] H. Doval,et al. Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.
[26] D. DeMets,et al. A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure , 1998 .
[27] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[28] Stuart J Pocock,et al. Current controversies in data monitoring for clinical trials , 2006, Clinical trials.
[29] Gordon H Guyatt,et al. Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.
[30] D. Rennie,et al. Stopping medical research to save money: a broken pact with researchers and patients. , 2003, JAMA.
[31] S. Pocock. When (not) to stop a clinical trial for benefit. , 2005, JAMA.
[32] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[33] G. Guyatt,et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. , 2010, JAMA.
[34] J. López-Sendón,et al. The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.
[35] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[36] Wojciech Zareba,et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.
[37] S. Pocock,et al. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2005, American heart journal.
[38] Boris Freidlin,et al. Bias and trials stopped early for benefit. , 2010, JAMA.
[39] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[40] G. Guyatt,et al. Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit , 2007, Annals of Internal Medicine.
[41] P C Deedwania,et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.
[42] S. Pocock,et al. Trials stopped early: too good to be true? , 1999, The Lancet.
[43] R. Ferrari,et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.